hydroxy-diphenyl-acetic acid l-(2-benzyloxy-acetvl)-pyrrolidin-3-ylmethyl ester | 877172-63-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: hydroxy-diphenyl-acetic acid l-(2-benzyloxy-acetvl)-pyrrolidin-3-ylmethyl ester
• 英文别名: hydroxv-diphenvl-acetic acid l-(2-benzvloxy-acetvl)-pyrrolidin-3-vlmethyl ester；[1-(2-Phenylmethoxyacetyl)pyrrolidin-3-yl]methyl 2-hydroxy-2,2-diphenylacetate
• CAS: 877172-63-9
• 化学式: C₂₈H₂₉NO₅
• 分子量: 459.542
• InChiKey: SCFNSVOXMNKXRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
  申请人：Salman Mohammad

  公开号：US20080262075A1

  公开（公告）日：2008-10-23

  This invention relates to pyrrolidine derivatives, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated through muscarinic receptors are also provided.

  本发明涉及吡咯烷衍生物，这些衍生物可用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和胃肠系统的各种疾病。本发明还提供了所述化合物的制备方法、含有所述化合物的制药组合物以及治疗通过毒蕈碱受体介导的疾病的方法。
• PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1781607A2

  公开（公告）日：2007-05-09
• [EN] PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRROLIDINE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS MUSCARINIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2006018708A2

  公开（公告）日：2006-02-23

  This invention relates to pyrrolidine derivatives, having the formula (I) which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated through muscarinic receptors are also provided.